Novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Lianhuaqingwen treatment group:6g/time, 3 times a day
Sponsors
The First Affiliated Hospital of Shandong First Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients infected with the Omicron variant; 2. Patients with mild or moderate clinical symptoms; 3. Patients vaccinated with novel Coronavirus vaccine; 4. Patients who can voluntarily sign written informed consent forms.
Exclusion criteria
Exclusion criteria: 1. Patients on antiviral or antibiotic drugs; 2. Chronic respiratory disease, respiratory bacterial infection and other respiratory diseases affecting the study; 3. Patients with serious primary diseases of heart, brain, lung, liver, kidney and hematopoietic systems, as well as mental diseases; 4. Patients with anaphylaxis to Lianhuaqingwen;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of disappearance of symptoms on day 14; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time of the nucleic acid test turns negative;Time of disappearance of antibody IgM;Absorption time of chest CT lesions; | — |
Countries
China
Contacts
Public ContactXuedong Liu/Liang Dong
The First Affiliated Hospital of Shandong First Medical University
Outcome results
None listed